NASDAQ:MIST Milestone Pharmaceuticals (MIST) Stock Price, News & Analysis $1.30 -0.02 (-1.14%) Closing price 03:58 PM EasternExtended Trading$1.32 +0.01 (+0.77%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Milestone Pharmaceuticals Stock (NASDAQ:MIST) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MIST alerts:Sign Up Key Stats Today's Range$1.28▼$1.4650-Day Range$0.65▼$2.4152-Week Range$0.63▼$2.75Volume1.70 million shsAverage Volume849,073 shsMarket Capitalization$69.63 millionP/E RatioN/ADividend YieldN/APrice Target$17.00Consensus RatingHold Company OverviewMilestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.Read More… Milestone Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreMIST MarketRank™: Milestone Pharmaceuticals scored higher than 38% of companies evaluated by MarketBeat, and ranked 678th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingMilestone Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageMilestone Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Milestone Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Milestone Pharmaceuticals are expected to decrease in the coming year, from ($0.62) to ($1.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Milestone Pharmaceuticals is -1.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Milestone Pharmaceuticals is -1.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMilestone Pharmaceuticals has a P/B Ratio of 2.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Milestone Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.66% of the float of Milestone Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverMilestone Pharmaceuticals has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Milestone Pharmaceuticals has recently increased by 6.25%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMilestone Pharmaceuticals does not currently pay a dividend.Dividend GrowthMilestone Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.66% of the float of Milestone Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverMilestone Pharmaceuticals has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Milestone Pharmaceuticals has recently increased by 6.25%, indicating that investor sentiment is decreasing significantly. News and Social Media3.2 / 5News Sentiment1.78 News SentimentMilestone Pharmaceuticals has a news sentiment score of 1.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Milestone Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 6 people have searched for MIST on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Milestone Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Milestone Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.90% of the stock of Milestone Pharmaceuticals is held by insiders.Percentage Held by Institutions86.18% of the stock of Milestone Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Milestone Pharmaceuticals' insider trading history. Receive MIST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Milestone Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address MIST Stock News HeadlinesMilestone Pharmaceuticals: A Golden Opportunity To Buy On Etripamil's CRL In PSVTApril 9, 2025 | seekingalpha.comMilestone Pharmaceuticals price target lowered to $10 from $25 at H.C. WainwrightApril 2, 2025 | markets.businessinsider.comHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.May 2, 2025 | Brownstone Research (Ad)TD downgrades Milestone Pharmaceuticals, suspends target on Etripamil uncertaintyApril 2, 2025 | finance.yahoo.comMilestone Pharmaceuticals (MIST) was downgraded to a Hold Rating at TD CowenApril 2, 2025 | markets.businessinsider.comMilestone Pharmaceuticals Shares Hit New Low After FDA Rejects EtripamilMarch 29, 2025 | marketwatch.comMilestone Pharmaceuticals Inc.: FDA Issues Complete Response Letter for Etripamil for PSVTMarch 28, 2025 | finanznachrichten.deMilestone stock tumbles after FDA letter on etripamilMarch 28, 2025 | ca.investing.comSee More Headlines MIST Stock Analysis - Frequently Asked Questions How have MIST shares performed this year? Milestone Pharmaceuticals' stock was trading at $2.36 at the beginning of the year. Since then, MIST shares have decreased by 45.1% and is now trading at $1.2950. View the best growth stocks for 2025 here. How were Milestone Pharmaceuticals' earnings last quarter? Milestone Pharmaceuticals Inc. (NASDAQ:MIST) announced its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.18) by $0.04. When did Milestone Pharmaceuticals IPO? Milestone Pharmaceuticals (MIST) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager. How do I buy shares of Milestone Pharmaceuticals? Shares of MIST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Milestone Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Milestone Pharmaceuticals investors own include OPKO Health (OPK), Corbus Pharmaceuticals (CRBP), Tilray (TLRY), VBI Vaccines (VBIV), CymaBay Therapeutics (CBAY), Vaxart (VXRT) and Aquestive Therapeutics (AQST). Company Calendar Last Earnings11/12/2024Today5/02/2025Next Earnings (Estimated)5/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MIST CIK1408443 Webwww.milestonepharma.com Phone(514) 336-0444FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$17.00 High Stock Price Target$25.00 Low Stock Price Target$9.00 Potential Upside/Downside+1,187.9%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-59,690,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-151.82% Return on Assets-49.85% Debt Debt-to-Equity Ratio2.18 Current Ratio15.40 Quick Ratio15.40 Sales & Book Value Annual Sales$1 million Price / Sales70.43 Cash FlowN/A Price / Cash FlowN/A Book Value$0.50 per share Price / Book2.64Miscellaneous Outstanding Shares53,354,000Free Float48,049,000Market Cap$70.43 million OptionableOptionable Beta1.38 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:MIST) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredElon Musk is all in on these robots …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Milestone Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Milestone Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.